Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sihuan Pharmaceutical Holdings Group Ltd.

四 環 醫 藥 控 股 集 團 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO STRATEGIC COOPERATION AGREEMENT BETWEEN JILIN HUISHENG BIOPHARMACEUTICAL AND PORTON PHARMA

The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that on 27 April 2021, Jilin Huisheng Biopharmaceutical Co., Ltd. ("Jilin Huisheng Biopharmaceutical"), an indirect non-wholly owned subsidiary of the Company held as to approximately 82.68% by the Group, entered into a strategic cooperation agreement with Porton Pharma Solutions Ltd. ("Porton Pharma"). Pursuant to the strategic cooperation agreement, Jilin Huisheng Biopharmaceutical and Porton Pharma will strategically cooperate in the therapeutic areas of diabetes and related complications in relation to the development and supply of active pharmaceutical ingredients and related preparations.

Jilin Huisheng Biopharmaceutical is a biopharmaceutical company focusing on comprehensive solutions for diabetes and related complications. It is one of the few leading companies in the PRC with full product coverage in the field of diabetes and related complications, with a pipeline of tens of high-quality diabetes and related complications products. Leveraging on the Group's network, Jilin Huisheng Biopharmaceutical is in the course of establishing its independent and highly efficient marketing network to enable the commercialization of its products in an efficient manner.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board

Sihuan Pharmaceutical Holdings Group Ltd.

Dr. Che Fengsheng

Chairman and Executive Director

Hong Kong, 28 April 2021

As

at the date of this announcement,

the executive directors of the Company

are Dr. Che Fengsheng (Chairman),

Dr.

Guo Weicheng (Deputy Chairman

and Chief Executive Officer), Dr. Zhang

Jionglong, Mr. Choi Yiau Chong and

Ms. Chen Yanling; the non-executive director of the Company is Mr. Kim Jin Ha; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.

Attachments

  • Original document
  • Permalink

Disclaimer

Sihuan Pharmaceutical Holdings Group Ltd. published this content on 28 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2021 11:01:06 UTC.